Abstract
The dengue virus (DENV) has been endemic in Myanmar since 1970, causing outbreaks every 2–3 years. DENV infection symptoms range from mild fever to lethal hemorrhage. Clinical biomarkers must be identified to facilitate patient risk stratification in the early stages of infection. We analyzed 45 cytokines and other factors in serum samples from the acute phase of DENV infection (within 3–5 days of symptom onset) from 167 patients in Yangon, Myanmar, between 2017 and 2019. All of the patients tested positive for serum DENV nonstructural protein 1 antigen (NS1 Ag); 78.4% and 62.9% were positive for immunoglobulin M (IgM) and G (IgG), respectively; and 18.0%, 19.8%, and 11.9% tested positive for serotypes 1, 3, and 4, respectively. Although the DENV-4 viral load was significantly higher than those of DENV-1 or DENV-3, disease severity was not associated with viral load or serotype. Significant correlations were identified between disease severity and CCL5, SCF, PDGF-BB, IL-10, and TNF-α levels; between NS1 Ag and SCF, CCL5, IFN-α, IL-1α, and IL-22 levels; between thrombocytopenia and IL-2, TNF-α, VEGF-D, and IL-6 levels; and between primary or secondary infection and IL-2, IL-6, IL-31, IL-12p70, and MIP-1β levels. These circulating factors may represent leading signatures in acute DENV infections, reflecting the clinical outcomes in the dengue endemic region, Myanmar.
Funding Information
  • Japan Agency for Medical Research and Development (AMED) (19jm0210047h0004, 21fk0108109h9903, 21wm0225018h0002, 21fk0108123h1602, JP21wm0125006)
  • AMED Research on Emerging and Re-emerging Infectious Diseases (19jm0210047h0004, 21fk0108109h9903, 21wm0225018h0002, 21fk0108123h1602, JP21wm0125006)
  • Japan Program for Infectious Diseases Research and Infrastructure (19jm0210047h0004, 21fk0108109h9903, 21wm0225018h0002, 21fk0108123h1602, JP21wm0125006)
  • Nagasaki University (19jm0210047h0004, 21fk0108109h9903, 21wm0225018h0002, 21fk0108123h1602, JP21wm0125006)

This publication has 48 references indexed in Scilit: